Urgent.News

the world's headlines, one feed

Editions

Health & Medicine

Epicrispr secures $90M after early data on epigenetic FSHD treatment

Epicrispr Biotechnologies has raised $90 million for its Series C round after sharing promising early data around a potential new way to treat a rare muscle disease called facioscapulohumeral muscular dystrophy. The Series C was ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine